- Home
- CTRM vs NRSN Comparison
CTRM vs NRSN Comparison
Compare CTRM & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | NRSN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Cyprus | Israel |
| Employees | N/A | 15 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 24.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTRM | NRSN |
|---|---|---|
| Price | $1.75 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 40.1K | ★ 183.4K |
| Earning Date | 05-13-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $0.63 |
| 52 Week High | $2.65 | $2.60 |
Technical Indicators
Market Signals| Indicator | CTRM | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 40.24 |
| Support Level | $1.66 | $0.66 |
| Resistance Level | $2.20 | $1.30 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 20.00 | 43.43 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.